Literature DB >> 7851281

Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine.

L Janiri1, P Mannelli, A M Persico, A Serretti, E Tempesta.   

Abstract

Thirty-nine methadone maintenance patients were included in a 9-day, double blind, randomized, inpatient detoxification trial. Methadone was tapered to 10 mg/day and then patients were assigned to one of these 3 protocols: clonidine (0.3-0.9 mg/day), lefetamine (60-240 mg/day), buprenorphine (0.15-0.9 mg/day). Buprenorphine treatment was significantly superior to clonidine and to lefetamine (F = 3.96 df = 2, 29 P < 0.05) in controlling objective, subjective and psychological withdrawal symptomatology. Clonidine was more effective than lefetamine in suppressing withdrawal in the first 3 days of treatment (day 3: F = 4.10 df = 2, 30 P < 0.05), and this trend was apparent on the objective and psychological items. In addition to evaluations of the efficacy of the single drugs used, the study showed that tapering methadone to low doses before entering the pharmacologically assisted discontinuation phase was clinically acceptable in detoxification from long-term methadone treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7851281     DOI: 10.1016/0376-8716(94)90096-5

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  17 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

2.  Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Miller; Paul A Nuzzo; Stacey C Sigmon
Journal:  Drug Alcohol Depend       Date:  2015-03-12       Impact factor: 4.492

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

4.  Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study.

Authors:  Syed Sajad Hussain; Samina Farhat; Yasir Hassan Rather; Zaffar Abbas
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 5.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

7.  Buprenorphine abuse in India : an update.

Authors:  Y Sharma; S K Mattoo
Journal:  Indian J Psychiatry       Date:  1999-04       Impact factor: 1.759

Review 8.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

Review 10.  Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Authors:  Jennifer S Orman; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.